"This Chesterfield Village Research Center is truly a world-class facility and our agreement with Pfizer will enable both of our companies to maintain our deep research roots in St. Louis for years to come," says Robb Fraley, Monsanto's chief technology officer. "The research we do at this facility is the foundation of our business, paving the way for next-generation products that create real benefits on the farm and in our world. This is yet another investment in our ever-growing pipeline, which enables us to deliver new and improved technologies."
The sale agreement includes the provision that Pfizer will be able to lease space for its biotherapeutic pharmaceutical research. Don Frail, VP of Pfizer, says, "We will continue to partner with Monsanto to ensure high-caliber research is ongoing in St. Louis, and that researchers from both companies will continue to share the Chesterfield Village Research Center."
In the deal Monsanto gets 1.3 million square feet, throughout 250 laboratories, 122 plant growth chambers and two acres of greenhouses. Before this deal, Monsanto leased more than 400,000 square feet of space in the Chesterfield Village.
The site, according to a release about the deal will "continue to support its robust pipeline, which is focused on increasing agricultural productivity such as drought-tolerant corn and higher-yielding soybeans, and will enable the company to reach its goal of doubling yields in its core crops by 2030."
The site was originally built in 1984 for $150 million by the former Monsanto Co.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.